Addex Therapeutics
Addex Therapeutics's email is info@addextherapeutics.com
and
Addex Therapeutics's phone number is 41228841555
.
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional ''orthosteric'' small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential f...
read more
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional ''orthosteric'' small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
show less
Website | addextherapeutics.com | |
Industry | Biotechnology | |
Location | Geneva, Switzerland | |
Employees | 26 | |
Founded | 2002 |
HQ | 12, chemin des Aulx Case postale 68 | |
Phone | 4122-884-1555 | |
info@addextherapeutics.com | ||
Funding | 185,233,725 USD | |
Competitors | Roche, Agilent Technologies, Amgen, Genentech, Eurofins, Gilead Sciences, |
Website | addextherapeutics.com | |
Industry | Biotechnology | |
Location | Geneva, Switzerland | |
Employees | 26 | |
Founded | 2002 | |
linkedin.com/company/addex-therapeutics | ||
HQ | 12, chemin des Aulx Case postale 68 | |
Phone | 4122-884-1555 | |
info@addextherapeutics.com | ||
Funding | 185,233,725 USD |
Email Patterns for Addex Therapeutics
Top Competitors for Addex Therapeutics
Addex Therapeutics Questions
Where are Addex Therapeutics's headquarters?
Addex Therapeutics's headquarters are in 12, chemin des Aulx Case postale 68
What is Addex Therapeutics's phone number?
Addex Therapeutics's phone number is 41228841555
What is Addex Therapeutics's official website?
Addex Therapeutics's website is addextherapeutics.com
How many employees are working in Addex Therapeutics right now?
Addex Therapeutics has
26 employees.
View the Email and Phone Numbers for all 26 working at Addex Therapeutics.
What is Addex Therapeutics's industry?
Addex Therapeutics's industry is
Biotechnology
Who are Addex Therapeutics's top competitors?
Addex Therapeutics's top competitors are
Roche
,
Agilent Technologies
,
Amgen
,
Genentech
,
Eurofins
,
Gilead Sciences
What is Addex Therapeutics's email address?
Addex Therapeutics's email address is info@addextherapeutics.com
What are Addex Therapeutics's categories?
Addex Therapeutics's categories are Biotechnology, Health Care, Medical, Pharmaceutical
What is Addex Therapeutics's location?
Addex Therapeutics's location is
Geneva, Switzerland
When was Addex Therapeutics's founded?
Addex Therapeutics's founding year is 2002
What is Addex Therapeutics's funding?
Addex Therapeutics's funding is 185,233,725 USD
What is Addex Therapeutics's current status?
Addex Therapeutics's current status is ipo
Top Addex Therapeutics Employees
Chief Medical Officer
roger.mills@addexpharma.com
+4122-884-1555
Controller
+1774-573-9109
Mechanical And Field Service Engineer
ncorso@iec-electronics.com
+1585-478-6596
Chairman Of The Board
rkraus@addexinc.com
+1781-344-5800
Executive Assistant To Chief Executive Officer
Directeur
Chief Executive Officer
timothy.dyer@addexpharma.com